Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > duration

: Hours per application

or N/A

or N/A (replacement)

Use the filters below to narrow your results.

Ciclopirox (1) · Clotrimazole (1) · Cyanocobalamin (vitamin B12) (1) · Ferrous sulfate (1) · Fluorouracil (5-FU) (1) · Folic acid (folate, pteroylglutamic acid) (1) · Hydroquinone (1) · Mupirocin (1) · Nystatin (1) · Riboflavin (vitamin B2) (1) · Tretinoin (all-trans retinoic acid, ATRA) (1)

Bactroban, Centany (1) · Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) · Feosol, Fer-In-Sol, Slow Fe; mostly generic and OTC (1) · Folvite; mostly generic (1) · Lotrimin, Mycelex, Gyne-Lotrimin; OTC widely (1) · Lustra, EpiQuin Micro, Melquin, Tri-Luma (with tretinoin and fluocinolone) (1) · Many generics/OTC (1) · Many OTC and Rx; Nascobal (intranasal); generic injection (1) · Mycostatin, Nystop, Nyamyc, Bio-Statin (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1) · Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL) (1)

APL)]] (1) · [[:Category:Antibacterials|Antibacterial]] (1) · [[:Category:Antifungals|Antifungal (imidazole)]] (1) · [[:Category:Antifungals|Antifungal]] (2) · [[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]] (1) · [[:Category:Antineoplastics|Antineoplastic (oral (1) · [[:Category:Antineoplastics|Antineoplastic]] (1) · [[:Category:B-vitamins|B-vitamin]] (3) · [[:Category:Depigmenting_agents|Depigmenting agent]] (1) · [[:Category:Hematinics|Hematinic]] (3) · [[:Category:Hydroxypyridones|Hydroxypyridone]] (1) · [[:Category:Iron_supplements|Iron supplement]] (1) · [[:Category:Polyene_antifungals|Polyene antifungal]] (1) · [[:Category:Retinoids|Retinoid]] (1) · [[:Category:Skin_lightening_agents|Skin-lightening agent]] (1) · [[:Category:Topical_antibiotics|Topical antibiotic]] (1) · [[:Category:Topical_antifungals|Topical antifungal]] (2) · [[:Category:Topical_retinoids|Topical retinoid]] (1) · [[:Category:Vitamins|Vitamin]] (3)

None (7) · '"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1) · '"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1) · '"`UNIQ--vote-0000124C-QINU`"' The 400 mg/d dose for migraine prophylaxis is supported by randomized trials (Schoenen 1998) and remains a low-risk evidence-based supplement option. Characteristic bright-yellow urine fluorescence with high-dose oral supplementation. (1)

0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) · 325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden (1) · Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis (1) · Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d (1) · Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks (1) · Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1) · Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1) · Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1) · Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days (1) · Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1)

0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection (1) · 0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) · 0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · 1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) · 100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual (1) · 100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets (1) · 2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal) (1) · 25, 50, 100, 250, 400 mg tablets; OTC (1) · 325 mg tablets (65 mg elemental Fe); 220 mg/5 mL liquid (44 mg elemental Fe/5 mL); 142 mg/mL drops; OTC and Rx (1) · 4% prescription cream/lotion; OTC 2% withdrawn in US (2020 CARES Act); compounded higher strengths available (1) · Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid) (1)

1 mg/d typical Rx; higher in specific indications (1) · 4% topical; limit duration of use (1) · BID topical; once daily nail lacquer (1) · Indication-specific (1) · Limit topical to 10-day courses to reduce resistance pressure (1) · No strict ceiling for water-soluble vitamin; UL not set (1) · No strict ceiling; water-soluble vitamin, low toxicity (1) · Topical: BID; troche: 5×/day (1) · Topical: nightly; oral APL: 45 mg/m²/d (1) · Topical: nightly; systemic: regimen-specific (1) · ~200 mg elemental iron/d typical practical limit (1)

IM (2) · intranasal (2) · IV (3) · IV (rare) (1) · Oral (4) · oral (APL only) (1) · Oral (topical action; minimal systemic absorption) (1) · oral troche (1) · SC (2) · sublingual (1) · Topical (7) · vaginal (2)

Days (2) · Days for dermatophyte clearance; nail clearance over months (1) · Hematologic response within days (1) · Migraine effect after 1-3 months of daily use (1) · Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1) · Reticulocyte response at 7-10 days; hemoglobin rise of ~1 g/dL per 3 weeks (1) · Symptom relief within days (1) · Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) · Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) · Visible lightening at 4-12 weeks (1)

N/A (incorporated into hemoglobin and tissue stores) (1) · Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) · Not meaningfully described (not systemically absorbed)'"`UNIQ--ref-00000D17-QINU`"' (1) · Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1) · Not meaningfully described for topical use'"`UNIQ--ref-00000A02-QINU`"' (1) · Not meaningfully described — topical local action with minimal systemic absorption'"`UNIQ--ref-00001218-QINU`"' (1) · ~0.5 hours plasma; tissue retention longer (1) · ~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) · ~1-2 hours plasma (riboflavin itself); FAD/FMN tissue cofactors are continuous (1) · ~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' (1) · ~6 days (plasma); hepatic stores last 3-5 years (1)

10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate) (1) · Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' (1) · High (oral) (1) · Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100% (1) · Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) · Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) · Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) · Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) · Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' (1) · ~50-60% (oral; food enhances) (1)

OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (1 mg, injectable) in US (1) · OTC (low/mid-dose oral) and [[USLegal:Prescription only|Rx-only]] (injection, intranasal) in US (1) · OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) · OTC in US (2) · [[USLegal:Prescription only|Rx-only]] in US (5) · [[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns) (1)

Showing below up to 11 results in range #1 to #11.

C